Global Glaucoma and Dry Eye Diseases Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Glaucoma and Dry Eye Diseases Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Glaucoma and Dry Eye Diseases are eye diseases. Glaucoma is a group of diseases characterized by characteristic optic atrophy and visual field defect, which seriously threaten human visual health. Dry Eye Diseases is an eye disease caused by multiple factors. The main symptoms are dry eyes, astringent eyes and foreign body sensation. This report classifies the products into Glaucoma Drugs, Dry Eye Diseases Drugs.

Market Overview:

The latest research study on the global Glaucoma and Dry Eye Diseases market finds that the global Glaucoma and Dry Eye Diseases market reached a value of USD 12236.71 million in 2022. It’s expected that the market will achieve USD 16742.74 million by 2028, exhibiting a CAGR of 5.36% during the forecast period.

The production process flow of drugs is complicated, and at the same time, due to the impact of the epidemic, the manufacturing of chemical raw materials and the manufacturing of pharmaceutical packaging materials are affected, which will lead to problems in the supply of raw materials in the process of drug production. This affects the normal production of industry companies. On the other hand, due to the outbreak of the new crown pneumonia epidemic, in order to prevent the further spread of the epidemic, the government has issued restrictions on people's travel and related isolation policies. The management efficiency of industry enterprises has declined, and the company's production plans have been affected.

In addition, due to the impact of the new coronavirus pneumonia epidemic, the number of outpatient visits in hospitals has decreased, pharmacies have been closed, and patient purchase channels have been limited, resulting in the company's production, sales and other work have been affected to varying degrees. However, during the epidemic, the Internet industry is booming, and the launch of a series of platforms for online e-commerce and online consultation will lead to an increase in online sales of drugs. In the long run, the client demand for the company's products has not decreased, but in the short term, it will have a certain impact on the operation of the industry company. In the face of sudden changes, industry companies need to formulate a number of emergency management measures in a timely manner. On the premise of doing their own epidemic prevention work, they should actively and orderly resume work and production to minimize the adverse impact of the epidemic on the company's operations and development.

Strength

Glaucoma is a group of diseases characterized by characteristic optic atrophy and visual field defect. It is the second leading cause of blindness in the world and seriously threatens human visual health. There is a certain genetic predisposition, and pathological intraocular pressure is the main risk factor. Usually can be divided into primary glaucoma, secondary glaucoma and congenital glaucoma three categories.
With the progression of the disease, various complications such as nausea, vomiting, fever, and rainbow vision may occur. In severe cases, blindness and glaucoma may occur and cannot be cured, but further damage to the optic nerve can be prevented through treatment. To avoid vision deterioration, patients need to use daily medication (most commonly eye drops). Most of the current glaucoma treatment drugs reduce intraocular pressure by reducing the production of aqueous humor in the eye or increasing the drainage of aqueous humor. These medicines can be eye drops, pills, or oral medicines. If not treated, it will lead to further damage to the optic nerve, resulting in decreased vision, visual field defects, seriously affecting vision, and causing a serious decline in quality of life. However, the use of therapeutic drugs can prevent vision loss and visual field loss in glaucoma patients, preserve existing vision, and improve quality of life.
For dry eye, patients often have symptoms such as dry eyes, easy fatigue, itchy eyes, foreign body sensation, burning sensation, thick secretions, and fear of wind. Blurred vision when seeing, but these symptoms of eye discomfort can be improved with long-term medication.

Weakness

There are many different causes of dry eye, so the symptoms of dry eye can vary. The best drug for treatment needs to be selected according to the category of dry eye. Due to the individual differences of each patient, the drugs used are also different.
For example, dry eye syndrome with insufficient tear secretion is often caused by the decreased function of the lacrimal or accessory lacrimal glands, resulting in a decrease in the ability of tear secretion, which may be related to immune diseases such as dryness. Dry eye in which excessive tear evaporation is associated with the function of the meibomian glands. After the meibomian glands are decompensated, the oily secretions of the meibomian glands cannot reach the ocular surface in time. Treatment methods such as anti-inflammatory drugs and meibomian gland massage and physiotherapy can be applied in this case, but the treatment time is relatively long, and drugs and physiotherapy are required at the same time.
But since dry eye is a very common eye disease, treatment drugs can be purchased through a variety of channels. And patients lack understanding of the disease, may purchase inappropriate drugs for treatment and thus fail to achieve the effect of treatment. Therefore, the wide variety of drugs and the lack of patient awareness of them is a disadvantage that limits the development of the industry.

Region Overview:

In global comparison, a significant portion of the revenue was generated in North America (35.88% in 2022).

Company Overview:

AbbVie is one of the major players operating in the Glaucoma and Dry Eye Diseases market, holding a share of 11.07% in 2022.

AbbVie

AbbVie is an American biotechnology company. AbbVie's mission is to discover and deliver innovative medicines to address today's serious health problems and address tomorrow's medical challenges. AbbVie strives to make a significant impact on people's lives in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology.

Novartis AG

Novartis AG is a multinational pharmaceutical and biotechnology company headquartered in Basel, Switzerland. Its core businesses are in a variety of patent medicines, consumer healthcare, generic medicines, eye care and animal health. Novartis AG uses innovative science and technology to solve some of society's most challenging healthcare problems.

Segmentation Overview:

As for product types, the Dry Eye Diseases Drugs segment held the largest market share in 2022.

Application Overview:

The market's largest segment by application is the segment Pharmacy Store, with a market share of 52.18% in 2022.

Key Companies in the global Glaucoma and Dry Eye Diseases market covered in Chapter 3:

AbbVie
Santen Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Bausch & Lomb Incorporated
Novartis AG
Viatris Inc.
Alcon
Aerie Pharmaceuticals, Inc.
Akorn, Inc.
Merck & Co., Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Glaucoma and Dry Eye Diseases market from 2018 to 2029 is primarily split into:

Glaucoma Drugs
Dry Eye Diseases Drugs

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Glaucoma and Dry Eye Diseases market from 2018 to 2029 covers:

Hospital
Pharmacy Store
Online Sales

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)